Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | TTK | P33981 | 1/20 | 0.36 |
| ▸ | RHEB | Q15382 | 1/20 | 0.34 |
| ▸ | LATS1 | O95835 | 1/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16041113 | 0.78 | ADORA2A (0.46) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL20783084 | 0.77 | PIK3C3 (0.50) | PIK3C3CCNA2CDK2TTKRHEB | |
| SCHEMBL21428757 | 0.76 | IKBKB (0.39) | PIK3C3 | |
| SCHEMBL20765319 | 0.75 | PIK3C3 (0.58) | PIK3C3CCNA2CDK2TTKRHEB | |
| SCHEMBL22537892 | 0.73 | SNCA (0.36) | — | |
| SCHEMBL30135066 | 0.72 | IKBKB (0.38) | — | |
| SCHEMBL30134984 | 0.71 | CDK9 (0.41) | CDK2CDK1GSK3B | |
| SCHEMBL18356291 | 0.69 | PIK3CD (0.40) | GSK3B | |
| SCHEMBL16041111 | 0.68 | CDK9 (0.47) | CDK2CDK1GSK3B | |
| SCHEMBL23347451 | 0.67 | KDM4A (0.35) | LATS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322772-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2023-10-12 | — | — | US | disclosed |
| US-20230322772-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2023-10-12 | — | — | US | disclosed |
| CN-116589461-A | Azaindolylpyridone compounds and diazaindolylpyridone compounds | 思普瑞特生物科学公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-116589462-A | Azaindolylpyridone compounds and diazaindolylpyridone compounds | 思普瑞特生物科学公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-111247144-B | Azaindolylpyridone compounds and diazaindolylpyridone compounds | 思普瑞特生物科学公司 | 2023-04-28 | — | — | CN | disclosed |
| US-11498919-B2 | Azaindolylpyridone and diazaindolylpyridone compounds | SPRINT BIOSCIENCE AB (SE) | 2022-11-15 | — | — | US | disclosed |
| EP-4001278-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | Sprint Bioscience AB (SE) | 2022-05-25 | — | — | EP | disclosed |
| EP-4001278-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | Sprint Bioscience AB (SE) | 2022-05-25 | — | — | EP | disclosed |
| EP-3672967-B1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3672967-B1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2021-10-06 | — | — | EP | disclosed |
| US-20210122745-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2021-04-29 | — | — | US | disclosed |
| US-20210122745-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2021-04-29 | — | — | US | disclosed |
| EP-3672967-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | Sprint Bioscience AB (SE) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019038384-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019038384-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322772-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | AZI2, IAPP, ZFX | PIK3C3 1407/4885CCNA2 425/4885CDK2 121/4885 |
| US-20210122745-A1 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | AZI2, IAPP, ZFX | PIK3C3 1407/4885CCNA2 425/4885CDK2 121/4885 |
| US-11498919-B2 | Azaindolylpyridone and diazaindolylpyridone compounds | AZI2, IAPP, ZFX | PIK3C3 1407/4885CCNA2 425/4885CDK2 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.